1319737-93-3

Basic information

• Product Name: (R)-4-{7-[4-(tetrahydro-pyran-4-yloxy)-3-trifluoromethyl-phenyl]-[1,6]naphthyridine-5-yloxymethyl}pyrrolidine-2-one
• Synonyms: (R)-4-{7-[4-(tetrahydro-pyran-4-yloxy)-3-trifluoromethyl-phenyl]-[1,6]naphthyridine-5-yloxymethyl}pyrrolidine-2-one
• CAS NO: 1319737-93-3
• Molecular Weight: 487.478
• Mol File: 1319737-93-3.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: (R)-4-{7-[4-(tetrahydro-pyran-4-yloxy)-3-trifluoromethyl-phenyl]-[1,6]naphthyridine-5-yloxymethyl}pyrrolidine-2-one(CAS DataBase Reference)
• NIST Chemistry Reference: (R)-4-{7-[4-(tetrahydro-pyran-4-yloxy)-3-trifluoromethyl-phenyl]-[1,6]naphthyridine-5-yloxymethyl}pyrrolidine-2-one(1319737-93-3)
• EPA Substance Registry System: (R)-4-{7-[4-(tetrahydro-pyran-4-yloxy)-3-trifluoromethyl-phenyl]-[1,6]naphthyridine-5-yloxymethyl}pyrrolidine-2-one(1319737-93-3)

Safety Data

• Hazardous Substances Data: 1319737-93-3(Hazardous Substances Data)

Upstream product

• 1165450-70-3 (R)-4-(hydroxymethyl)pyrrolidine-2-one 
• 1319737-54-6 5-chloro-7-[4-(tetrahydro-pyran-4-yloxy)-3-trifluoromethyl-phenyl]-[1,6]naphthyridine 
• 190957-22-3 (4R,1'R)-1-(1'-phenylethyl)-4-hydroxymethylpyrrolidin-2-one 
• 99735-43-0 (3R)-1-((R)-1-phenylethyl)-5-oxo-3-pyrrolidinecarboxylic acid 

Relevant articles and documents

SUBSTITUTED NAPHTHYRIDINES AND THEIR USE AS MEDICAMENTS

The invention relates to new substituted naphthyridines of formula 1, as well as pharmacologically acceptable salts, diastereomers, enantiomers, racemates, hydrates or solvates thereof, wherein R1 is selected from among —O—R3 or —NR3R4,R3 is C1-6-alkyl which is substituted by R5 and R6,R5 is selected from hydrogen, branched or linear C1-6-alkyl, C2-6-alkenyl, —C1-6-alkylen-O—C1-3-alkyl, C1-3-haloalkyl,R6 is ring X wherein n is either 0 or 1, and is a either a single or a double bond andwherein A, B, D and E are each independently from one another selected from CH2, CH, C, N, NH, O or S and wherein ring X is attached to the molecule either via position A, B, D or E, wherein said ring X may optionally be further substituted by one, two or three residues each selected individually from the group consisting of -oxo, hydroxy, —C1-3-alkyl, —C1-3-haloalkyl, —O—C1-3-alkyl, —C1-3-alkanol and halogen,and wherein R4, R2, R7, R8, R9, R10, R11 and Q may have the meanings as given in claim 1, as well as pharmaceutical compositions containing these compounds.